Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $19
Benzinga Newsdesk 3 hours ago
Analyst RatingsNewsPrice Target
Barclays analyst Etzer Darout maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and raises the price target from $18 to $19.
Barclays analyst Etzer Darout maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and raises the price target from $18 to $19.